Adeno-associated viral (aav) vectors for tissue-targeted expression of therapeutic genes
US-2024285804-A1 · Aug 29, 2024 · US
MGMT-based method for obtaining high yields of recombinant protein expression
US9109219B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9109219-B2 |
| Application number | US-201113824476-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 9, 2011 |
| Priority date | Dec 9, 2010 |
| Publication date | Aug 18, 2015 |
| Grant date | Aug 18, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a novel enhancer of protein production in host cells. It discloses a vector for expressing recombinant proteins in these cells, comprising a nucleotide sequence encoding a) a secretion peptidic signal, b) a 6-methylguanine-DNA-methyltransferase enzyme (MGMT, EC 2.1.1.63), a mutant or a catalytic domain thereof, and c) a recombinant protein. Said MGMT enzyme is preferably the so-called SNAP protein.
First claim
Opening claim text (preview).
The invention claimed is: 1. A vector for expressing recombinant proteins in isolated host cells, comprising a nucleotide sequence encoding in a single open reading frame, from 5′ to 3′: a) a peptidic secretion signal which is functional in said isolated host cells, b) a 6-methylguanine-DNA-methyltransferase enzyme (MGMT) or mutant thereof, wherein said MGMT enzyme or MGMT mutant is the protein of SEQ ID NO:2, or a homologous sequence thereof that is at least 80% identical to SE…
Assignees
Inventors
Classifications
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
- C12N15/625Primary
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
- C12N9/1007Primary
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9109219B2 cover?
- The present invention relates to a novel enhancer of protein production in host cells. It discloses a vector for expressing recombinant proteins in these cells, comprising a nucleotide sequence encoding a) a secretion peptidic signal, b) a 6-methylguanine-DNA-methyltransferase enzyme (MGMT, EC 2.1.1.63), a mutant or a catalytic domain thereof, and c) a recombinant protein. Said MGMT enzyme is p…
- Who is the assignee on this patent?
- Despres Philippe, Paulous Sylvie, Crublet Elodie, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C12N15/625. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 18 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).